Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 70.35
+4.80 (7.32%)
Aug 20, 2026, 4:09 PM HKT
Shanghai Henlius Biotech Market Cap
Shanghai Henlius Biotech has a market cap or net worth of 38.23 billion as of August 20, 2026. Its market cap has decreased by -15.09% in one year.
Market Cap
38.23B
Enterprise Value
41.30B
Revenue
7.42B
Ranking
n/a
PE Ratio
41.87
Stock Price
70.35
ChartMarket Cap Chart
Since September 25, 2019, Shanghai Henlius Biotech's market cap has increased from 26.66B to 38.23B, an increase of 43.42%. That is a compound annual growth rate of 5.36%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 20, 2026 | 38.23B | 23.31% |
| Dec 31, 2025 | 31.01B | 140.72% |
| Dec 31, 2024 | 12.88B | 70.50% |
| Dec 29, 2023 | 7.55B | 8.59% |
| Dec 30, 2022 | 6.96B | -41.95% |
| Dec 31, 2021 | 11.98B | -53.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Sino Biopharmaceutical | 85.29B |
| Akeso | 82.26B |
| RemeGen | 69.08B |
| Genscript Biotech | 64.21B |
| Biocytogen Pharmaceuticals (Beijing) | 58.15B |
| 3SBio | 41.59B |
| Shanghai Junshi Biosciences | 38.13B |
| InnoCare Pharma | 29.93B |